Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis

Pediatric Pulmonology

Volumn 44, Issue 8, 2009, Pages 820-825

  Ferroni, Agnes ^a   Guillemot, Didier ^b   Moumile, Kaoutar ^a   Bernede, Claire ^b   Le Bourgeois, Muriel ^a   Waernessyckle, Serge ^a   Descamps, Philippe ^a   Sermet Gaudelus, Isabelle ^a   Lenoir, Gérard ^a   Berche, Patrick ^a   Taddei, François ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

Author keywords

Antibiotic resistance; Cystic fibrosis; Lung function; Mutator Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFSULODIN; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTERIUM MUTANT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISK DIFFUSION; DRUG SENSITIVITY; FORCED EXPIRATORY VOLUME; HUMAN; INFANT; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SPUTUM ANALYSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VITAL CAPACITY;

EID: 68049096879     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21076     Document Type: Article

References (19)

1. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005;49:2276-2282. (Pubitemid 40734454)
2. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. Hypermutation is a key factor in development of multipleantimicrobial multiple antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005;49:3382-3386. (Pubitemid 41060586)
3. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288:1251-1254. (Pubitemid 30367204)
4. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003;187:1709-1716. (Pubitemid 36667881)
5. Roman F, Canton R, Perez-Vazquez M, Baquero F, Campos J. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol 2004;42: 1450-1459. (Pubitemid 38500780)
6. Giraud A, Matic I, Radman M, Fons M, Taddei F. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 2002;46:863-865. (Pubitemid 34157676)
7. Henrichfreise B, Wiegand I, PfisterW, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 2007;51:4062-4070. (Pubitemid 350057805)
8. Miller JH. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu Rev Microbiol 1996; 50:625-643.
9. Oliver A, Baquero F, Blazquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002;43:1641-1650. (Pubitemid 34595553)
10. Giraud A, Matic I, Tenaillon O, Clara A, Radman M, Fons M, Taddei F. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 2001;291:2606-2608. (Pubitemid 32249685)
11. Sniegowski PD, Gerrish PJ, Lenski RE. Evolution of high mutation rates in experimental populations of E. coli. Nature 1997;387:703-705. (Pubitemid 27270609)
12. Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH, Godelle B. Role of mutator alleles in adaptive evolution. Nature 1997;387:700-702. (Pubitemid 27270608)
13. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008;190:7910-7917.
14. Blazquez J. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 2003;37: 1201-1209. (Pubitemid 37372510)
15. Hogardt M, Hoboth C, Schmoldt S, Henke C, Bader L, Heesemann J. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 2007;195:70-80. (Pubitemid 44958228)
16. Picard B, Duriez P, Gouriou S, Matic I, Denamur E, Taddei F. Mutator natural Escherichia coli isolates have an unusual virulence phenotype. Infect Immun 2001;69:9-14. (Pubitemid 32038293)
17. Mena A, Macia MD, Borrell N, Moya B, de Francisco T, Perez JL, Oliver A. Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J Bacteriol 2007;189:3665-3668. (Pubitemid 46668834)
18. Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tummler B, Cariani L, Conese M, Doring G, Bragonzi A. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 2007;153:1445-1454. (Pubitemid 46780000)
19. Spencker FB, Haupt S, Claros MC, Walter S, Lietz T, Schille R, Rodloff AC. Epidemiologic characterization of Pseudomonas